Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Update

Coya Therapeutics, Inc. (NASDAQ:COYA) was the target of a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 181,000 shares, a drop of 7.9% from the October 31st total of 196,500 shares. Based on an average trading volume of 77,800 shares, the days-to-cover ratio is presently 2.3 days. Currently, 1.2% of the company’s stock are sold short.

Analysts Set New Price Targets

Several equities analysts recently commented on COYA shares. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday, November 11th. Chardan Capital reiterated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Thursday, November 7th.

Insider Activity

In other Coya Therapeutics news, CEO Arun Swaminathan purchased 5,000 shares of Coya Therapeutics stock in a transaction dated Monday, November 11th. The shares were acquired at an average cost of $7.34 per share, with a total value of $36,700.00. Following the completion of the transaction, the chief executive officer now owns 5,000 shares in the company, valued at approximately $36,700. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders have purchased 9,510 shares of company stock worth $69,615. 9.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Coya Therapeutics

Several hedge funds have recently modified their holdings of COYA. Vanguard Group Inc. raised its holdings in Coya Therapeutics by 772.3% in the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after purchasing an additional 750,338 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Coya Therapeutics in the second quarter valued at approximately $101,000. GHP Investment Advisors Inc. acquired a new position in Coya Therapeutics during the third quarter worth about $169,000. Gilbert & Cook Inc. purchased a new stake in Coya Therapeutics in the 2nd quarter valued at $61,000. Finally, Geode Capital Management LLC raised its stake in Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after purchasing an additional 4,485 shares during the period. 39.75% of the stock is owned by hedge funds and other institutional investors.

Coya Therapeutics Price Performance

COYA traded down $0.31 during midday trading on Tuesday, hitting $6.04. 203,463 shares of the company were exchanged, compared to its average volume of 69,052. The company’s 50 day simple moving average is $7.18 and its 200 day simple moving average is $6.82. Coya Therapeutics has a 1-year low of $4.75 and a 1-year high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.15. Research analysts predict that Coya Therapeutics will post -1.15 earnings per share for the current year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.